Kurokawa I, Akamatsu H, Nishijima S, Asada Y, Kawabata S
Department of Dermatology, Kansai Medical University, Osaka, Japan.
J Am Acad Dermatol. 1991 Oct;25(4):674-81. doi: 10.1016/0190-9622(91)70252-w.
Twenty-eight patients with acne were assigned to 4 weeks of treatment with OPC-7251 (a new fluoroquinolone derivative) 1% cream or the cream base in a double-blind manner to evaluate the antibacterial effect of the drug on resident bacteria in the hair follicles and to evaluate clinical response. Propionibacterium acnes was isolated from 21 of the 28 acne patients. When the number of P. acnes was compared before and after treatment, the posttreatment P. acnes count in the OPC-7251 1% cream group was significantly (p = 0.000) reduced compared with that in the cream base group. OPC-7251 1% cream was also significantly (p = 0.019) superior to the cream base in terms of clinical response. P. acnes and Staphylococcus epidermidis isolated from the acne lesions were selected for their susceptibility to various antibacterial agents. The minimal inhibitory concentration of OPC-7251 against P. acnes and S. epidermidis was 0.10 to 0.20 and 0.024 to 0.10 micrograms/ml, respectively, which indicates that the drug has a potent antibacterial effect.
28名痤疮患者被双盲分配接受为期4周的1%OPC - 7251（一种新型氟喹诺酮衍生物）乳膏或乳膏基质治疗，以评估该药物对毛囊常驻细菌的抗菌效果并评估临床反应。28名痤疮患者中有21名分离出痤疮丙酸杆菌。比较治疗前后痤疮丙酸杆菌的数量时，1%OPC - 7251乳膏组治疗后的痤疮丙酸杆菌计数与乳膏基质组相比显著降低（p = 0.000）。在临床反应方面，1%OPC - 7251乳膏也显著优于乳膏基质（p = 0.019）。从痤疮皮损中分离出的痤疮丙酸杆菌和表皮葡萄球菌被用于检测它们对各种抗菌剂的敏感性。OPC - 7251对痤疮丙酸杆菌和表皮葡萄球菌的最低抑菌浓度分别为0.10至0.20微克/毫升和0.024至0.10微克/毫升，这表明该药物具有强效抗菌作用。
